-+ 0.00%
-+ 0.00%
-+ 0.00%

Tenax Therapeutics names Thomas R. Staab CFO, replacing interim CFO Thomas McGauley

PUBT·04/22/2026 11:04:21
Listen to the news
Tenax Therapeutics names Thomas R. Staab CFO, replacing interim CFO Thomas McGauley
  • Tenax Therapeutics named Thomas R. Staab II as chief financial officer, effective May 11, 2026.
  • Staab most recently served as CFO and secretary of LENSAR.
  • His prior roles include CFO positions at BioCryst Pharmaceuticals, Inspire Pharmaceuticals, Triangle Pharmaceuticals.
  • Thomas McGauley will be replaced as interim CFO, a role he has held since December 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220700PRIMZONEFULLFEED9694454) on April 22, 2026, and is solely responsible for the information contained therein.